OPA1: Potential Drug Target Or Biomarker for Optic Atrophy (G4976)
![Review Report on OPA1 Target / Biomarker](https://silexon.ai/img/target-biomarker-review.jpg?a=1)
![Content of Review Report on OPA1 Target / Biomarker](https://silexon.ai/img/target-biomarker-review-content.jpg?a=2)
OPA1: Potential Drug Target Or Biomarker for Optic Atrophy
OPA1 (Optic atrophy 1) is a gene that encodes a protein known as optic atrophy protein 1. OPA1 is a protein that is expressed in the retina and is involved in the development and progression of optic atrophy. Optic atrophy is a group of genetic disorders that is characterized by the progressive loss of vision.
OPA1 is a transmembrane protein that is expressed in the retina and is involved in the development and progression of optic atrophy. It is made up of 154 amino acids and has a calculated molecular weight of 19.8 kDa. OPA1 is expressed in the retina and is involved in the development and progression of optic atrophy.
Studies have shown that OPA1 is involved in the development and progression of optic atrophy. For example, researchers have found that OPA1 is highly expressed in the retina and is involved in the development of optic atrophy in mice. Additionally, they have found that OPA1 is involved in the progression of optic atrophy in human samples.
OPA1 may be a drug target or biomarker for the treatment of optic atrophy. Researchers are currently studying the potential therapeutic effects of OPA1 in the treatment of optic atrophy. For example, researchers have found that OPA1 may be a potential drug target for the treatment of optic atrophy because it is involved in the development and progression of the condition. Additionally, they have found that OPA1 may be a useful biomarker for the diagnosis of optic atrophy.
In conclusion, OPA1 is a protein that is involved in the development and progression of optic atrophy. It may be a potential drug target or biomarker for the treatment of the condition. Further research is needed to fully understand the role of OPA1 in optic atrophy and to develop effective treatments.
Protein Name: OPA1 Mitochondrial Dynamin Like GTPase
Functions: Dynamin-related GTPase that is essential for normal mitochondrial morphology by regulating the equilibrium between mitochondrial fusion and mitochondrial fission (PubMed:16778770, PubMed:17709429, PubMed:20185555, PubMed:24616225, PubMed:28746876). Coexpression of isoform 1 with shorter alternative products is required for optimal activity in promoting mitochondrial fusion (PubMed:17709429). Binds lipid membranes enriched in negatively charged phospholipids, such as cardiolipin, and promotes membrane tubulation (PubMed:20185555). The intrinsic GTPase activity is low, and is strongly increased by interaction with lipid membranes (PubMed:20185555). Plays a role in remodeling cristae and the release of cytochrome c during apoptosis (By similarity). Proteolytic processing in response to intrinsic apoptotic signals may lead to disassembly of OPA1 oligomers and release of the caspase activator cytochrome C (CYCS) into the mitochondrial intermembrane space (By similarity). Plays a role in mitochondrial genome maintenance (PubMed:20974897, PubMed:18158317)
The "OPA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OPA1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OPA1-AS1 | OPA3 | OPALIN | OPCML | OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P | OR11L1 | OR11M1P | OR12D2 | OR12D3 | OR13A1 | OR13C2 | OR13C3 | OR13C4 | OR13C5 | OR13C8 | OR13C9 | OR13D1 | OR13F1 | OR13G1 | OR13H1 | OR13J1 | OR13Z2P | OR14A16 | OR14A2 | OR14C36 | OR14I1 | OR14J1 | OR14L1P | OR1A1